Global Retirement Partners’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.56K Sell
205
-5
-2% -$185 ﹤0.01% 3872
2026
Q2
$8.13K Buy
+210
New +$7.35K ﹤0.01% 3494
2025
Q4
$37.1K Buy
+1,045
New +$29.4K ﹤0.01% 2529
2023
Q3
– Sell
-121
Closed -$1.43K – 3266
2023
Q2
$1.43K Sell
121
-1,201
-91% -$13.8K ﹤0.01% 2660
2023
Q1
$15K Hold
1,322
– – ﹤0.01% 1763
2022
Q4
$15.3K Sell
1,322
-500
-27% -$6.2K ﹤0.01% 1597
2022
Q3
$25K Hold
1,822
– – ﹤0.01% 1285
2022
Q2
$16K Hold
1,822
– – ﹤0.01% 1435
2022
Q1
$8K Hold
1,822
– – ﹤0.01% 1698
2021
Q4
$16K Hold
1,822
– – 0.01% 128
2021
Q3
$15K Hold
1,822
– – ﹤0.01% 1293
2021
Q2
$15K Hold
1,822
– – ﹤0.01% 1269
2021
Q1
$16K Buy
1,822
+121
+7% +$1.16K ﹤0.01% 1165
2020
Q4
$19K Buy
+1,701
New +$18.7K ﹤0.01% 1044

Other funds holding COGT

Global Retirement Partners's COGT Position: Q3 2026 in Review

Global Retirement Partners reduced its Cogent Biosciences (COGT) stake by 2.4% in Q3 2026, selling an estimated $185 and leaving 205 shares worth $6.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3872.

Global Retirement Partners first reported a position in COGT in Q4 2020 and has held it in 14 quarters since. The position peaked at $37.1K in Q4 2025. 316 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Global Retirement Partners held 205 shares of Cogent Biosciences worth $6.56K as of Q3 2026.
  • Global Retirement Partners sold 5 Cogent Biosciences shares in Q3 2026, an estimated $185.
  • Cogent Biosciences made up ﹤0.01% of Global Retirement Partners's portfolio in Q3 2026, its #3872 holding.
  • Global Retirement Partners first reported a position in Cogent Biosciences in Q4 2020 and has held it in 14 quarters since.
  • Global Retirement Partners's Cogent Biosciences position peaked at $37.1K in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Global Retirement Partners's 13F filing for Q3 2026, filed 10 Nov 2026.